Context: A counterfeit medicine racket in Bengaluru has exposed serious gaps in drug-quality monitoring and supply-chain oversight in Karnataka.
- Relabelled, fake and expired medicines, including cancer drugs and ICU injections, were supplied to more than 90 hospitals and clinics across the State.
- The racket came to light after raids near Bidadi, Karnataka, on August 18 uncovered suspected fake and expired medicines at an unlicensed farmhouse unit.
- The seized consignment had a label value of around ₹5 crore, indicating the potentially large scale of the operation.
Modus Operandi of the Racket
- The farmhouse was allegedly used to repack fake and expired medicines, alter expiry dates and market them as fresh consignments.
- Some medicines were allegedly presented as expensive imported branded drugs and sold at substantial discounts to attract buyers.
- Investigators found a distribution network operating through a Bengaluru pharmacy, with supplies reaching over 90 healthcare facilities.
- The Karnataka Government subsequently constituted a Special Investigation Team (SIT) to trace the wider network and identify those involved.
- Investigators are examining possible inter-State links and conducting a comprehensive review of the medicine supply chain.
- The role of private hospitals and possible complicity within the private healthcare network is also under investigation.
Major Concerns: Patient Safety and Regulatory Failure
- The primary concern is patient safety, as several counterfeit medicines involved are intended for critical and time-sensitive medical interventions.
- Fake or substandard medicines may cause adverse reactions, treatment failure, disability or death, particularly when used for critical illnesses.
- The ability of the racket to operate on a large scale indicates possible weaknesses in market surveillance, licensing, inspection and supply-chain verification.
- The case also raises concerns about the due diligence exercised by healthcare institutions and pharmacies while procuring medicines.
India’s Drug-Quality Challenge
- Incidents involving poor-quality, spurious, counterfeit and expired drugs continue to periodically expose weaknesses in India's pharmaceutical quality-control system.
- This is particularly significant for India because of its ambition to become the “pharmacy of the world” and a major global supplier of affordable medicines.
- India's pharmaceutical reputation depends not merely on production capacity and affordability but also on consistent compliance with stringent quality standards.
- Recent instances of contaminated cough syrups causing deaths in India and other countries have further intensified concerns regarding pharmaceutical quality and manufacturing oversight.
Key Terms: Drug Quality
- Spurious drug: A medicine deliberately manufactured or sold under a false identity, generally involving fraudulent claims about its manufacturer, composition or origin.
- Counterfeit/falsified medicine: A medicine deliberately misrepresented regarding its identity, composition or source; it may contain incorrect, inadequate or no active pharmaceutical ingredient.
- Substandard medicine: A legitimately manufactured medicine that fails to meet prescribed quality specifications, often because of manufacturing or storage problems.
- Expired medicine: A medicine used or marketed beyond its approved shelf life, after which its safety, efficacy or stability cannot be assured.
Way Forward
- Strengthen risk-based inspections and post-market surveillance of medicines, particularly high-risk and life-saving drugs.
- Digitise the pharmaceutical supply chain to enable batch-level traceability from manufacturer to pharmacy and healthcare facility.
- Tighten verification of manufacturing licences, distributors, pharmacies and repackaging units, with strict action against unlicensed facilities.
- Strengthen coordination among drug regulators, police, hospitals and other enforcement agencies to detect organised counterfeit-drug networks.
- Ensure that medicines manufactured in India meet globally credible quality standards, irrespective of whether they are intended for domestic consumption or export.
Regulatory Architecture
- Drug regulation in India involves both the Central and State Governments, with responsibilities distributed between central regulatory authorities and State drug-control administrations.
- The Central Drugs Standard Control Organisation (CDSCO) functions under the Ministry of Health and Family Welfare and is India's central drug regulatory authority.
- The Drugs and Cosmetics Act, 1940 and Drugs and Cosmetics Rules, 1945 constitute the core legal framework governing the import, manufacture, distribution and sale of drugs and cosmetics.
- Effective regulation therefore requires not only stringent laws but also adequate testing capacity, inspections, enforcement and continuous surveillance after medicines enter the market.
